Aspect Partners
KRYS icon

Aspect Partners’s Krystal Biotech KRYS Stock Holding History

Aspect Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.33K Hold
10
– – ﹤0.01% 467
2026
Q2 		$3.72K Buy
+10
New +$2.99K ﹤0.01% 460

Other funds holding KRYS

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Yousif Capital Management
Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return
Quantum Private Wealth
Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Aspect Partners's KRYS Position: Q3 2026 in Review

Aspect Partners held its Krystal Biotech (KRYS) position steady in Q3 2026 at 10 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #467.

Aspect Partners first reported a position in KRYS in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.72K in Q2 2026. 72 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Aspect Partners held 10 shares of Krystal Biotech worth $3.33K as of Q3 2026.
  • Aspect Partners left its Krystal Biotech share count unchanged in Q3 2026.
  • Krystal Biotech made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #467 holding.
  • Aspect Partners first reported a position in Krystal Biotech in Q2 2026 and has held it in 2 quarters since.
  • Aspect Partners's Krystal Biotech position peaked at $3.72K in Q2 2026.
  • 72 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.